Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to MarketBeat Daily Ratings so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:CERC

Cerecor (CERC) Stock Price, News & Analysis

→ Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad)
Free CERC Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$8.92
▼
$10.07
50-Day Range
$2.06
▼
$3.24
52-Week Range
$1.98
▼
$4.50
Volume
64,464 shs
Average Volume
1.27 million shs
Market Capitalization
$920.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsInsider TradesSocial Media
CERC stock logo

About Cerecor Stock (NASDAQ:CERC)

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

CERC Stock News Headlines

December 19, 2023 | benzinga.com
Aytu BioPharma Stock (NASDAQ:AYTU) Insider Trades
August 24, 2023 | uk.finance.yahoo.com
mTOR Inhibitors Global Market Report 2023
May 11, 2023 | finance.yahoo.com
DelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Crohn's Disease Pipeline Landscape
September 28, 2022 | finance.yahoo.com
Edited Transcript of AYTU.OQ earnings conference call or presentation 27-Sep-22 8:30pm GMT - Yahoo Finance
September 28, 2022 | seekingalpha.com
Aytu BioPharma, Inc. (AYTU) CEO Josh Disbrow on Q4 2022 Results - Earnings Call Transcript - Seeking Alpha
August 31, 2022 | marketwatch.com
DiGeorge Syndrome Drug Market In-Depth Analysis Research Report 2029
August 24, 2022 | streetinsider.com
ValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors - StreetInsider.com
August 24, 2022 | businesswire.com
ValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors - Business Wire
August 11, 2022 | globenewswire.com
Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update - GlobeNewswire
August 9, 2022 | streetinsider.com
Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update - StreetInsider.com
August 8, 2022 | marketscreener.com
Celldex Therapeutics : Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Form 8-K - Marketscreener.com
July 24, 2022 | seekingalpha.com
Avalo Therapeutics, Inc. (AVTX) Stock Price Today, Quote & News - Seeking Alpha
July 15, 2022 | bizjournals.com
Philadelphia biotech news: Updates from CHOP, Helius Medical, GSK and more - Philadelphia Business Journal - The Business Journals
May 3, 2022 | prnewswire.com
The Axial Spondyloarthritis Market is Predicted to Grow with a CAGR of 4.7% by 2032, Analyzes DelveInsight - PR Newswire
May 1, 2022 | marketwatch.com
DiGeorge Syndrome Drug Market Size, Share, Industry Growth & Forecast By 2029
April 8, 2022 | marketscreener.com
AACR Poster Presentation: CFT7455 Phase 1/2 Cohort A - Marketscreener.com
March 28, 2022 | benzinga.com
DiGeorge Syndrome Drug Market High Demand, Size, Share, Processing Industry, And Forecast By 2029 - Benzi - Benzinga
November 10, 2021 | businesswire.com
Model N Announces Fourth Quarter and Fiscal Year 2021 Financial Results - Business Wire
November 10, 2021 | nasdaq.com
Model N (MODN) Q4 Earnings & Revenues Top Estimates, Up Y/Y - Nasdaq
November 9, 2021 | finance.yahoo.com
Model N Announces Fourth Quarter and Fiscal Year 2021 Financial Results - Yahoo Finance
November 9, 2021 | finance.yahoo.com
Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates - Yahoo Finance
November 9, 2021 | stockhouse.com
Model N Announces Fourth Quarter and Fiscal Year 2021 Financial Results - Stockhouse
October 7, 2021 | finance.yahoo.com
Horizon Technology Finance Provides Third Quarter 2021 Portfolio Update - Yahoo Finance
August 27, 2021 | bizjournals.com
Inovio's experimental Covid-19 vaccine takes another step, plus other life sciences news - Philadelphia Business Journal - Philadelphia Business Journal
August 27, 2021 | marketscreener.com
CERECOR : Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc (Form 8-K) - Marketscreener.com
See More Headlines

Company Calendar

Last Earnings
8/01/2021
Today
5/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CERC
CUSIP
N/A
CIK
1534120
Web
www.cerecor.com
Phone
(410) 522-8707
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-63,500,000.00
Net Margins
-1,194.82%
Pretax Margin
N/A
Return on Equity
-261.82%
Return on Assets
-133.96%

Debt

Debt-to-Equity Ratio
0.79
Current Ratio
2.19
Quick Ratio
2.18

Sales & Book Value

Annual Sales
$6.70 million
Price / Sales
137.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.22 per share
Price / Book
43.59

Miscellaneous

Outstanding Shares
96,009,000
Free Float
N/A
Market Cap
$920.73 million
Optionable
Not Optionable
Beta
1.44

Key Executives

  • Michael F. Cola
    Chairman & Chief Executive Officer
  • Schond L. Greenway
    Chief Financial Officer & Treasurer
  • H. Jeffrey Wilkins
    Chief Medical Officer
  • Garry Arthur NeilGarry Arthur Neil
    Chief Scientific Officer
  • Younok Dumortier Shin
    Chief Technology Officer

Key Competitors

View All Competitors

CERC Stock Analysis - Frequently Asked Questions

How were Cerecor's earnings last quarter?

Cerecor Inc. (NASDAQ:CERC) issued its quarterly earnings results on Sunday, August, 1st. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The firm earned $3.36 million during the quarter. Cerecor had a negative net margin of 1,194.82% and a negative trailing twelve-month return on equity of 261.82%.

What other stocks do shareholders of Cerecor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerecor investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), KushCo (KSHB), Novan (NOVN), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

This page (NASDAQ:CERC) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
Next President (Not Trump. Not Biden.)
The Freeport Society
Urgent Nvidia Warning
Altimetry
Elon’s New Device is About to Shock the World
InvestorPlace
"The Biggest Drug Ever" Is Coming
Behind the Markets
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders